• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Heartbeam Inc.

    6/25/26 8:30:01 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    DEFA14A 1 ea0295892-defa14a_heart.htm DEFINITIVE ADDITIONAL MATERIALS

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

     

    Filed by the Registrant ☒ Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to § 240.14a-12

     

    Heartbeam, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required
    ☐ Fee paid previously with preliminary materials
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

      

     

     

     

    Supplement to the Definitive Proxy Statement

    for the 2026 Annual Meeting of Shareholders

    To be Held on Friday, July 31, 2026

     

    This proxy supplement dated June 25, 2026 (this “Supplement”), supplements the definitive proxy statement of Heartbeam, Inc. (the “Company”) filed with the Securities and Exchange Commission on June 18, 2026 (the “Proxy Statement”). The Proxy Statement relates to the Company’s 2026 Annual Meeting of Shareholders, which is scheduled to be held on Friday, July 31, 2026 (the “Annual Meeting”).

     

    This Supplement provides supplemental information concerning the Annual Meeting and the matters to be considered at the Annual Meeting and is filed primarily for the purpose of describing a recent change in the proposed nominees for election to the Board of Directors of the Company (the “Board”), and should be read in conjunction with the Proxy Statement.

     

    Withdrawal of Nominee for Election as Director

     

    On June 18, 2026, Mark Strome, a member of the Board and a nominee for re-election as a director at the Annual Meeting, gave notice of his decision to resign from the Board, effective June 18, 2026, for personal reasons and not as the result of a dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. As a result, the nomination of Mr. Strome is withdrawn, and no other nominee for election at the Annual Meeting will be named in place of Mr. Strome.

     

    On June 18, 2026, the Company and Rob Eno, Chief Executive Officer of the Company and a member of the Board and a nominee for re-election as a director at the Annual Meeting, mutually agreed to his departure as the Company’s Chief Executive Officer and as a member of the Board, effective as of June 30, 2026, in connection with a strategic reorganization within the Company. Mr. Eno’s decision to depart is not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. As a result, the nomination of Mr. Eno is withdrawn, and no other nominee for election at the Annual Meeting will be named in place of Mr. Eno.

     

    Voting Matters

     

    If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote. Proxies or voting instruction forms already returned by shareholders will remain valid and will be voted at the Annual Meeting unless revoked. Shares represented by proxies returned before the Annual Meeting will be voted for the directors nominated by the Board as instructed on the proxy card or voting instruction form, except that votes will not be cast for Mr. Strome and Mr. Eno, because each director has resigned from the Board and is no longer standing for re-election. If you have not yet returned your proxy card or submitted your voting instructions, please complete the proxy card or submit voting instructions, disregarding Mr. Strome’s and Mr. Eno’s name as nominees for the election of directors.

     

    None of the other agenda items presented in the Proxy Statement are affected by this Supplement, and shares represented by proxy returned before the Annual Meeting will be voted with respect to all other matters properly brought before the Annual Meeting as instructed on your proxy card or voting instruction form. Important information regarding how to vote your shares and revoke proxies already cast is available in the Proxy Statement under the caption “Can I change my mind after I return my proxy?”.

     

    THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

     

      

     

    Get the next $BEAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    4/20/2026Buy → Hold
    D. Boral Capital
    3/31/2026$4.00Buy
    B. Riley Securities
    3/27/2026$5.00Buy
    D. Boral Capital
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    12/8/2025$2.50Buy
    H.C. Wainwright
    10/31/2025$4.00Buy
    Roth Capital
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition

    Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating with a leaner, more focused structure Company to provide more details on strategy as part of Second Quarter 2026 conference call in August HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operation

    6/24/26 4:05:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home

    Publication in JACC: Advances demonstrates that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack risk Study advances the scientific foundation supporting HeartBeam's planned indication expansion into heart attack detection Large market potential with over 20 million patients in the U.S. at risk of a heart attack HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a peer-reviewed article in JACC: Advances, a journal of the American College of Cardiology, demonstrating that a risk prediction algorithm incorpor

    6/2/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Reports First Quarter 2026 Results

    Signed First Commercial Partners in Leading Concierge Practices ClearCardio™ and Atelier Health Established Flagship Commercial Sites Across New York, Dallas, South Florida and Southern California Strategic Collaboration with Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms, Starting with Heart Attack Detection Strengthened Balance Sheet with $11.5 Million Public Offering Including Full Exercise of Over-Allotment Option Initiated Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Initiated Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic Management to Host Webcast and Conference Call Today

    5/13/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    SEC Filings

    View All

    SEC Form DEFA14A filed by Heartbeam Inc.

    DEFA14A - HeartBeam, Inc. (0001779372) (Filer)

    6/25/26 8:30:01 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - HeartBeam, Inc. (0001779372) (Filer)

    6/24/26 5:28:27 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - HeartBeam, Inc. (0001779372) (Filer)

    6/22/26 4:15:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Ferrari Richard bought $46,000 worth of shares (57,500 units at $0.80), increasing direct ownership by 25% to 286,636 units (SEC Form 4)

    4/A - HeartBeam, Inc. (0001779372) (Issuer)

    4/24/26 4:05:03 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Cruickshank Tim

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:48:21 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Elfrink Willem

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:48:07 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HeartBeam downgraded by D. Boral Capital

    D. Boral Capital downgraded HeartBeam from Buy to Hold

    4/20/26 8:06:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on HeartBeam with a new price target

    B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    3/31/26 8:12:24 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on HeartBeam with a new price target

    D. Boral Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $5.00

    3/27/26 8:50:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Ferrari Richard bought $46,000 worth of shares (57,500 units at $0.80), increasing direct ownership by 25% to 286,636 units (SEC Form 4)

    4/A - HeartBeam, Inc. (0001779372) (Issuer)

    4/24/26 4:05:03 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 8:00:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 7:55:14 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

    Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

    5/5/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

    First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

    12/16/24 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Financials

    Live finance-specific insights

    View All

    HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition

    Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating with a leaner, more focused structure Company to provide more details on strategy as part of Second Quarter 2026 conference call in August HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operation

    6/24/26 4:05:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2026, and will be providing updates on key strategic growth initiatives, including its limited commercial launch for arrhythmia assessment, and developments on its extended-wear patch, heart attack detection and AI initiatives. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answe

    4/30/26 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    10/25/23 4:01:55 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    8/28/23 4:26:34 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    6/2/23 2:36:13 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care